Frontier Capital Management CO LLC Neurocrine Biosciences Inc Transaction History

Frontier Capital Management CO LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$86.91 - $108.33 $1.72 Million - $2.14 Million	-19,782 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $1.98 Million - $2.78 Million	-20,580 Reduced 50.99%	19,782 $1.9 Million
Q2 2020 Jul 17, 2020	BUY	$85.09 - $130.36 $3.43 Million - $5.26 Million	40,362 New	40,362 $4.92 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $13.6 Million - $17.2 Million	-188,328 Closed	0 $0
Q1 2019 May 07, 2019	SELL	$69.31 - $91.53 $12.1 Million - $16 Million	-175,144 Reduced 48.19%	188,328 $16.6 Million
Q4 2018 Jan 25, 2019	SELL	$68.32 - $124.36 $2.89 Million - $5.25 Million	-42,242 Reduced 10.41%	363,472 $26 Million
Q3 2018 Oct 30, 2018	SELL	$98.88 - $125.85 $23.9 Million - $30.4 Million	-241,209 Reduced 37.29%	405,714 $49.9 Million
Q2 2018 Aug 03, 2018	SELL	$75.3 - $105.99 $13.5 Million - $19 Million	-179,349 Reduced 21.71%	646,923 $63.6 Million
Q1 2018 Apr 30, 2018	BUY	$75.88 - $92.43 $53.6 Million - $65.3 Million	706,047 Added 587.27%	826,272 $68.5 Million
Q4 2017 Jan 18, 2018	BUY	$58.53 - $77.59 $7.04 Million - $9.33 Million	120,225	120,225 $9.33 Million

627

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.